year 3, Issue 12 (11-2004)                   J. Med. Plants 2004, 3(12): 33-42 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ziai S, Larijani B, Fakhrzadeh H, Dastpak A, Bandarian F, Rezai A et al . Study of Psyllium (Plantago ovata L.) effects on diabetes and lipidemia in the Iranian type II diabetic patients.. J. Med. Plants. 2004; 3 (12) :33-42
URL: http://jmp.ir/article-1-727-en.html
1- Department pharmacology, Institute of Medicinal Plants ACECR , ziai2000@hotmail.com
2- Endocrinology & Metabolism Research Center, Tehran University of Medical Sciences, Tehran
3- Department pharmacology, Institute of Medicinal Plants ACECR
4- Iran Darouk Co. Tehran
5- Department Cultivation & Development, Institute of Medicinal Plants, ACECR and Tarbiat Modarres Uniiversity, Tehran, Iran.
Abstract:   (5187 Views)
Psyllium is a bulk-forming laxative and is high in both fiber and mucilage. The beneficial effect of dietary fiber in the management of type II diabetes has not been totally demonstrated. The purpose of this study was to determine the plasma- lowering effects of 5 g b.i.d. of psyllium husk fiber, as an adjunct to dietary therapy, on lipid and glucose levels, in Iranian patients with type II diabetes. Patients were randomly selected from an outpatient clinic of primary care to participate in a double-blind placebo-controlled study in which Plantago Psyllium or placebo was given in combination with a low fat diet. Forty-nine subjects were included in the study that were given diet counseling before and then followed an 8-week treatment period. Fasting plasma glucose was measured every 2 weeks, and total plasma cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and insulin levels were measured every 4 weeks. Glycosylatd hemoglobin was also measured at the beginning and end of the treatment period. The test products (psyllium or placebo) were supplied to subjects in identically labeled foil packets containing a 5-g dose of product, to consume two doses per day (of 5 g each one), half an hour before breakfast and dinner. Both products were well tolerated, with no serious adverse events related to treatment reported in either. Some of the psyllium patients reported that their gastric tolerance to metformin became better. Fasting plasma glucose, and Glycosylated hemoglobin, showed a significant reduction (p < 0.05), whereas HDL cholesterol increased significantly (p < 0.05) following Psyllium treatment. Our results show that 5 g b.i.d. of Psyllium for persons with diabetes is safe, is well tolerated, and improves glycemic and lipid control in patients with type 2 diabetes and hypercholesterolemia.
Full-Text [PDF 231 kb]   (2107 Downloads)    
Type of Study: Research | Subject: Pharmacology & Toxicology
Received: 2004/01/2 | Accepted: 2004/10/9 | Published: 2004/12/15

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb